Literature DB >> 23488891

Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia.

R A Maselli1, J Arredondo, J Nguyen, M Lara, F Ng, M Ngo, J M Pham, Q Yi, J M Stajich, K McDonald, M A Hauser, R L Wollmann.   

Abstract

The term 'limb-girdle myasthenia' (LGM) was first used to describe three siblings with proximal limb weakness without oculobulbar involvement, but with EMG decrement and responsiveness to anticholinesterase medication. We report here that exome sequencing in the proband of this family revealed several sequence variations in genes linked to proximal limb weakness. However, the only mutations that cosegregated with disease were an intronic IVS7-8A>G mutation and the previously reported 3'-UTR c.*22C>A mutation in GFPT1, a gene linked to LGM. A minigene assay showed that IVS7-8A>G activates an alternative splice acceptor that results in retention of the last seven nucleotides of intron 7 and a frameshift leading to a termination codon 13 nucleotides downstream from the new splice site. An anconeus muscle biopsy revealed mild reduction of the axon terminal size and postsynaptic fold simplification. The amplitudes of miniature endplate potentials and quantal release were also diminished. The DNA of the mildly affected father of the proband showed only the intronic mutation along with sequence variations in other genes potentially relevant to LGM. Thus, this study performed in the family originally described with LGM showed two GFPT1 untranslated mutations, which may cause disease by reducing GFPT1 expression and ultimately impairing protein glycosylation.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  GFPT1; congenital myasthenic syndromes; limb-girdle myasthenia; neuromuscular junction; whole-exome sequencing

Mesh:

Substances:

Year:  2013        PMID: 23488891     DOI: 10.1111/cge.12118

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Whole-exome sequencing reveals a rare interferon gamma receptor 1 mutation associated with myasthenia gravis.

Authors:  Guoyan Qi; Peng Liu; Shanshan Gu; Hongxia Yang; Huimin Dong; Yinping Xue
Journal:  Neurol Sci       Date:  2018-02-13       Impact factor: 3.307

2.  Congenital myasthenic syndromes.

Authors:  Josef Finsterer
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

3.  The changing paradigm of intron retention: regulation, ramifications and recipes.

Authors:  Geoffray Monteuuis; Justin J L Wong; Charles G Bailey; Ulf Schmitz; John E J Rasko
Journal:  Nucleic Acids Res       Date:  2019-12-16       Impact factor: 16.971

4.  Diverse myopathological features in the congenital myasthenia syndrome with GFPT1 mutation.

Authors:  Kaiyan Jiang; Yilei Zheng; Jing Lin; Xiaorong Wu; Yanyan Yu; Min Zhu; Xin Fang; Meihong Zhou; Xiaobing Li; Daojun Hong
Journal:  Brain Behav       Date:  2022-01-03       Impact factor: 3.405

5.  Abnormal decrement on high-frequency repetitive nerve stimulation in congenital myasthenic syndrome with GFPT1 mutations and review of literature.

Authors:  Ran An; Huijiao Chen; Song Lei; Yi Li; Yanming Xu; Chengqi He
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

6.  GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice.

Authors:  Yasmin Issop; Denisa Hathazi; Muzamil Majid Khan; Rüdiger Rudolf; Joachim Weis; Sally Spendiff; Clarke R Slater; Andreas Roos; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2018-09-15       Impact factor: 6.150

7.  Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations.

Authors:  Lisa E Creary; Sridevi Gangavarapu; Stacy J Caillier; Paola Cavalcante; Rita Frangiamore; Benedicte A Lie; Mats Bengtsson; Hanne Flinstad Harbo; Susanna Brauner; Jill A Hollenbach; Jorge R Oksenberg; Pia Bernasconi; Angelina Hatlø Maniaol; Lennart Hammarström; Renato Mantegazza; Marcelo A Fernández-Viña
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.